Cambridge Antibody Tech Group PLC
30 September 2005
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically.
To: The FSA
Date: 30 September 2005
Name of applicant: Cambridge Antibody Technology
Group plc
Name of scheme: Company Share Option Plan
Period of return: From: 1 April 2005 To: 30 September 2005
Balance under scheme from previous return: 266,232
The amount by which the block scheme Nil
has been increased, if the scheme has been
increased since the date of the last return:
Number of securities issued/allotted under 25,854
scheme during period:
Balance under scheme not yet issued/allotted 240,378
at end of period
Number and class of securities originally 22,136,251 ordinary
listed and the date of admission 10 pence shares
25 March 1997
Total number of securities in issue at 51,639,868
the end of the period
Name of contact: Justin Hoskins
Address of contact: Milstein Building, Granta Park,
Cambridge CB1 6GH
Telephone number of contact: 01223 471 471
SIGNED BY Justin Hoskins, Company Secretary
Director/company secretary/suitably experienced employee/duly authorised
officer,
for and on behalf of
Cambridge Antibody Technology Group plc
Name of applicant
If you knowingly or recklessly give false or misleading information you may be
liable to prosecution.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.